Rabbit Monoclonal FGFR2 Antibody

Fibroblast Growth Factor Receptor 2 (FGFR2) is a transmembrane tyrosine kinase receptor critical for regulating cell proliferation, differentiation, migration, and survival during embryonic development, tissue repair, and disease. Dysregulation of FGFR2 signaling, caused by gene amplification, mutations, or aberrant expression, is implicated in various cancers (e.g., breast, gastric, and endometrial cancers) and developmental disorders (e.g., craniosynostosis syndromes). FGFR2-targeting antibodies are engineered to modulate FGFR2 activity, either by blocking ligand binding, inhibiting receptor dimerization, or promoting receptor internalization. These antibodies serve as valuable tools for studying FGFR2’s biological roles and as therapeutic agents. In oncology, FGFR2 inhibitors, including monoclonal antibodies and small-molecule tyrosine kinase inhibitors, are being explored to counteract tumor growth and metastasis driven by FGFR2 overexpression or mutations. Additionally, FGFR2 antibodies are used in diagnostics to detect receptor expression patterns in tissues, aiding cancer subtyping and prognosis. Challenges in therapeutic development include addressing isoform-specificity (FGFR2 has multiple splice variants), minimizing off-target effects, and overcoming drug resistance. Recent advances in antibody engineering, such as bispecific antibodies or antibody-drug conjugates, aim to enhance precision and efficacy. Overall, FGFR2 antibodies represent a promising avenue for both understanding FGFR2-related pathologies and developing targeted therapies.